Liu Jian Joins Guangzhou Pharma Group as Chief Strategic Scientist, Former BeiGene Executive Brings Extensive Biopharma Leadership

Guangzhou Pharmaceutical Holdings Limited recently announced that Liu Jian has joined the company as its Strategic Scientist. Prior to joining Guangzhou Pharmaceutical Holdings Limited, Liu Jian served asBeOneMember of the Global Executive Committee, CEO of the Innovation Center, and Chairman of Biologics. He led the innovative drug incubation business at BeOne’s Innovation Center and oversaw the development of BeOne’s biologics manufacturing facility in Guangzhou. Additionally, Mr. Liu Jian has many years of experience in new drug development, investment and financing management, and pharmaceutical distribution at Pfizer, Sanofi, AstraZeneca, Novartis, and Johnson & Johnson Pharmaceuticals, making him a senior expert and executive in the innovative drug industry.

As the newly appointed Strategic Scientist at Guangzhou Pharmaceutical Holdings Limited, Liu Jiancheng will become a core member of the company’s strategic development for innovation-driven transformation, spearheading efforts in tackling major diseases, establishing an innovative drug pipeline, and facilitating the commercialization of scientific and technological achievements.

Li Xiaojun, Secretary of the Party Committee and Chairman of Guangzhou Pharmaceutical Holdings Limited, stated that Liu Jian’s appointment marks a milestone in the company’s efforts to attract high-level talent, significantly enhancing its top-level design capabilities and strategic execution in the biopharmaceutical sector.

As the leading enterprise in Guangzhou’s biomedical industry chain, Guangzhou Pharmaceutical Holdings Limited has intensified its efforts in recent years to attract high-level talent from both domestic and international markets. The company has launched the “5+5” High-End Leading Talent Plan, aiming to build a top-tier expert team across five strategic fields—cell and gene therapy, antibody drugs, nucleic acid drugs, nuclear medicine, and AI-enabled R&D—by recruiting professionals at five hierarchical levels: Strategic Scientist, Chief Scientist, Senior Scientist, Advanced Scientist, and Research Expert.

Currently, Guangzhou Pharmaceutical Holdings Limited has recruited or is in the process of recruiting nearly 20 high-end leading talents under its “5+5” initiative, including Liu Jian. Among them are many senior R&D professionals and business development (BD) specialists for innovative drugs with work experience at top international pharmaceutical companies such as Johnson & Johnson, Eli Lilly, Merck & Co., Novartis, and AstraZeneca. Meanwhile, the company has engaged more than 40 top domestic and international experts, including academicians Rao Zihe and Ma Jun, to establish a top-tier scientific and technological innovation think tank for the group. It currently employs over 400 experts with senior professional titles, more than 135 individuals holding doctoral or postdoctoral qualifications, and over 20 other high-level talents.

Looking Ahead to the “15th Five-Year Plan” Period, Guangzhou Pharmaceutical Holdings Limited Has Clearly Defined Its Strategy to Vigorously Develop the “4+4+X” Business Framework. The Company Will Consolidate Its Four Core Pillars—Modern Traditional Chinese Medicine, Chemical Pharmaceutical Technology, Pharmaceutical Commerce, and Natural Beverages—to Strengthen Its Industrial Foundation. Simultaneously, It Will Aggressively Cultivate Four Growth Engines: Biopharmaceutical Innovation, Consumer Health, Diagnostic Devices, and Agricultural Technology, While Also Deploying “X” Extended Segments Such As Asset Operations. Over the Next Five Years, Guangzhou Pharmaceutical Holdings Limited Plans to Invest RMB 20 Billion in R&D and Allocate RMB 30 Billion for Mergers and Acquisitions, Driving Growth Through a Dual-Engine Strategy of “In-House R&D + M&A.”

Currently, Guangzhou Pharmaceutical Holdings Limited is accelerating its strategic layout in cutting-edge fields such as cell and gene therapy, nucleic acid drugs, radiopharmaceuticals, monoclonal/bispecific/multispecific antibodies, and antibody-drug conjugates (ADCs). Leveraging a high-caliber talent pool and the innovative empowerment of over 100 research platforms and 19 national-level research institutions under its umbrella, the Group currently has nearly 200 R&D projects underway. These projects extensively cover major disease areas, including malignant tumors, chronic disease management, respiratory diseases, immune system disorders, and andrology.

Furthermore, Guangzhou Pharmaceutical Holdings Limited is leading the establishment of the Greater Bay Area Center for Regional Technology Transfer and Commercialization of Biopharmaceuticals in Universities across China. The center’s layout encompasses multiple sub-platforms covering CGT drugs such as stem cells, immune cells, viruses, plasmids, and mRNA, as well as peptide and antibody drugs. It provides end-to-end translational R&D services ranging from proof-of-concept and animal studies to pilot-scale production, and is actively facilitating the implementation of the first batch of 33 collaborative CGT projects.